AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Hao Tang

Hao Tang

Bristol-Myers Squibb Co. - New York / United States
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 4396407
-
person_outline Hao Tang's MOST POPULAR ARTICLES
1-) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial The Lancet 389 (10088), 2492-2502, 2017
2-) A community effort to assess and improve drug sensitivity prediction algorithms Nature biotechnology 32 (12), 1202-1212, 2014
3-) NRF2 regulates serine biosynthesis in non–small cell lung cancer Nature genetics 47 (12), 1475-1481, 2015
4-) 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth Cell reports 5 (3), 637-645, 2013
5-) Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma Journal of hepatology 73 (6), 1460-1469, 2020